市場調查報告書

Remicade生技仿製藥的全球市場:各種類、技術、服務、用途、地區的預測

Remicade Biosimilar Market: By Type, By Technology, By Service, By Application, By Region-Forecast 2019-2024

出版商 IndustryARC 商品編碼 422456
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
Remicade生技仿製藥的全球市場:各種類、技術、服務、用途、地區的預測 Remicade Biosimilar Market: By Type, By Technology, By Service, By Application, By Region-Forecast 2019-2024
出版日期: 2018年12月14日內容資訊: 英文
簡介

本報告提供全球Remicade生技仿製藥的市場相關分析,產品概要和整體市場結構,主要的推動及阻礙市場要素,各類型、各技術、各類服務、各地區的市場趨勢預測 (今後6年分),市場競爭概況,近來的資本交易、策略發展的動向,主要企業簡介等調查評估。

第1章 Remicade生技仿製藥:市場概要

第2章 摘要整理

第3章 市場環境

  • 市場佔有率分析
  • 比較分析
  • 產品的互相比較
  • 終端用戶簡介
  • 前五名公司的財務分析

第4章 Remicade生技仿製藥市場影響要素

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 課題
  • 波特的五力分析

第5章 Remicade生技仿製藥市場:策略分析

  • 價值鏈分析
  • 價格趨勢分析
  • 市場機會分析
  • 產品/市場生命週期分析
  • 供應商、經銷商

第6章 Remicade生技仿製藥市場:各類型

  • 基因改造型、非醣化蛋白質
  • 基因改造型、醣化蛋白質

第7章 Remicade生技仿製藥市場:各技術

  • 單株抗體 (MAb) 技術
  • 基因改造型DNA技術 (rDNA技術)
  • 核磁共振 (NMR) 技術
  • 層析法 (顏色層分析)
  • 電泳
  • 質譜分析
  • 西方墨點法
  • 生物檢測 (生物審定)

第8章 Remicade生技仿製藥市場:各類服務

  • CRAMS (醫藥品研究開發、受託製造服務)
  • 臨床實驗

第9章 Remicade生技仿製藥市場:各用途

  • 血液疾病
  • 腫瘤
  • 慢性疾病/自體免疫疾病
  • 生長激素缺乏症
  • 其他

第10章 Remicade生技仿製藥市場:各地區

  • 歐洲 (德國、法國、義大利、西班牙、俄羅斯、英國等)
  • 亞太地區 (中國、日本、印度、韓國等)
  • 北美 (美國、加拿大、墨西哥)
  • 其他的國家 (RoW) (巴西等)

第11章 Remicade生技仿製藥市場:市場變化的方向性

  • 產業擴張
  • 技術開發
  • 企業合併、收購 (M&A),合資企業
  • 供給契約

第12章 企業簡介

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Remicade biosimilar market globally being driven by primary factors like development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, growing prevalence of chronic diseases among aging population. In addition, increase in adoption of remicade biosimilar in emerging economies such as China, India and others, will create new opportunities for global remicade biosimilar market. However, higher cost of the research and development, and stringent government regulations are the key restraints for global remicade biosimilar market.

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, growing prevalence of chronic diseases among aging population are the prime growth drivers of global remicade biosimilar market. In addition, increase in adoption of remicade biosimilar in emerging economies such as China, India and others, will create new opportunities for global remicade biosimilar market. However, higher cost of the research and development, and stringent government regulations are the key restraints for global remicade biosimilar market.

Geographically European dominated global remicade biosimilar market because of favourable regulatory policies designed by the European Medical Association, high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing prevalence of chronic diseases in developing nations such as China, and India in this region. Among all the application, oncology segment has the highest market share in global remicade biosimilar market due to higher prevalence of cancer patients.

This report identifies the global remicade biosimilar market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global remicade biosimilar market.

This report segments global remicade biosimilar market on the basis of type, technology, service, application, and regional market as follows:

Remicade Biosimilar Market, By Type: Recombinant Non-Glycosylated Protein, Recombinant Glycosylated Protein, and Peptides

Remicade Biosimilar Market, By Technology: Monoclonal Antibodies (MAb) Technology, Recombinant DNA Technology (rDNA), Nuclear Magnetic Resonance (NMR) Technology, Chromatography, Electrophoresis, Mass Spectrometry, Western Blotting, and Bioassay

Remicade Biosimilar Market, By Service: Contract Research and Manufacturing Services (CRAMS), and Clinical Trials

The report has focused study on remicade biosimilar market by basis of application such as: Blood Disorders, Oncology Diseases, Chronic and Autoimmune Diseases, Growth Hormone Deficiencies, and Others

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the remicade biosimilar market. Some of the major companies' profiles in detail are as follows:

Teva Pharmaceutical Industries Ltd.

Synthon Pharmaceuticals, Inc.

LG Life Sciences

Novartis (Sandoz)

Celltrion

Table of Contents

1. Remicade Biosimilar Market - Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Remicade Biosimilar Market- Market Forces

  • 4.1. Drivers
    • 4.1.1. Development of efficient and advance technology
    • 4.1.2. Higher expiration patent
  • 4.2. Restraints
    • 4.2.1. Higher cost of research and development
  • 4.3. Opportunities
    • 4.3.1. Emerging economies
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Remicade Biosimilar Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Remicade Biosimilar Market, By Type

  • 6.1. Recombinant Non-Glycosylated Protein
  • 6.2. Recombinant Glycosylated Protein
  • 6.3. Peptides

7. Remicade Biosimilar Market, By Technology

  • 7.1. Monoclonal Antibodies (Mab) Technology
  • 7.2. Recombinant DNA Technology (rDNA Technology)
  • 7.3. Nuclear magnetic resonance (NMR) Technology
  • 7.4. Chromatography
  • 7.5. Electrophoresis
  • 7.6. Mass Spectrometry
  • 7.7. Western Blotting
  • 7.8. Bioassay

8. Remicade Biosimilar Market, By Service

  • 8.1. Contract Research and Manufacturing Services (CRAMS)
  • 8.2. Clinical Trials

9. Remicade Biosimilar Market, By Application

  • 9.1. Blood Disorders
  • 9.2. Oncology Diseases
  • 9.3. Chronic and Autoimmune Diseases
  • 9.4. Growth Hormone Deficiencies
  • 9.5. Others

10. Remicade Biosimilar Market, By Geography

  • 10.1. Europe
    • 10.1.1. Germany
    • 10.1.2. France
    • 10.1.3. Italy
    • 10.1.4. Spain
    • 10.1.5. Russia
    • 10.1.6. U.K.
    • 10.1.7. Rest of Europe
  • 10.2. Asia Pacific
    • 10.2.1. China
    • 10.2.2. India
    • 10.2.3. Japan
    • 10.2.4. South Korea
    • 10.2.5. Rest of Asia-Pacific
  • 10.3. North America
    • 10.3.1. U.S.
    • 10.3.2. Canada
    • 10.3.3. Mexico
  • 10.4. Rest of the World (RoW)
    • 10.4.1. Brazil
    • 10.4.2. Rest of RoW

11. Remicade Biosimilar - Market Entropy

  • 11.1. Expansion
  • 11.2. Technological Developments
  • 11.3. Merger & Acquisitions, and Joint Ventures
  • 11.4. Supply- Contract

12. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 12.1. Teva Pharmaceutical Industries Ltd.
  • 12.2. Synthon Pharmaceuticals, Inc.
  • 12.3. LG Life Sciences
  • 12.4. Novartis (Sandoz)
  • 12.5. Celltrion
  • 12.6. Biocon
  • 12.7. Hospira
  • 12.8. Merck Serono (Merck Group)
  • 12.9. Biogen idec Inc.
  • 12.10. Genentech (Roche Group)

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

13. Appendix

  • 13.1. Abbreviations
  • 13.2. Sources
  • 13.3. Research Methodology
  • 13.4. Bibliography
  • 13.5. Compilation of Expert Insights
  • 13.6. Disclaimer